The optimal use of cisplatin for the best treatment of solid tumors has been prevented because of dose limiting nephro-and ototoxicity. Higher doses of cisplatin may be used with chemoprotectants such as diethyldithiocarbamate (DDTC), which prevents cisplatin toxicity for the kidney and bone marrow. Our preliminary data suggest that DDTC can also prevent cisplatin ototoxicity in an animal model. The proposed research seeks to address the basic question, """"""""Can the ototoxicity of cisplatin be altered by manipulating the glutathione (GSH) content of the cochlea?"""""""" A corollary is that the GSH content of the cochlea is related to enzymes of the antioxidant system [superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px)] and the enzymes glutathione reductase (GR) and glutathione-S-transferase (GST) and that these enzymes are affected by cisplatin.
The specific aims are: 1) to investigate the hypothesis that cisplatin ototoxicity is related to the diminution of the antioxidant system in the cochlea, and that such changes are specific for this target tissue. Physiological changes measured with auditory brainstem evoked response (ABER) testing and endocochlear potential (EP) measurements will be correlated with a) ultrastructural alterations using scanning electron microscopy (SEM) of the organ of Corti and transmission electron microscopy (TEM) of the stria vascularis; and b) biochemical changes in the antioxidant system of the cochlea in comparison to nontarget tissues, the liver and heart, 2) to test the hypothesis that some or all of the ototoxic injury caused by cisplatin is mediated by ototoxic metabolites such as GSH adducts, 3) to examine the hypothesis that the prevention of cisplatin ototoxicity by DDTC is mediated by preservatives of the antioxidant system in the cochlea, 4) to study the pharmacokinetics of cisplatin in plasma and cochlear tissues in ototoxic rats and in animals receiving cisplatin plus the rescue agent, DDTC. The techniques used for this investigation will involve the expertise of three investigators namely physiological measurements (ABER and EP), morphological studies (SEM and TEM) biochemical and metabolic studies: (HPLC) with ultraviolet and electrochemical detection (GSH and GSSG), antioxidant enzymes and other enzymes of the glutathione pathway using spectrophotometry and pharmacokinetic studies by atomic absorption spectrophotometry of platinum levels. These studies should provide new insights into the mechanisms of cisplatin ototoxicity and mechanisms for protection from this dose-limiting side effect arising from use of this life-saving chemotherapeutic agent.

Agency
National Institute of Health (NIH)
Institute
National Institute on Deafness and Other Communication Disorders (NIDCD)
Type
Research Project (R01)
Project #
5R01DC002396-04
Application #
2443624
Study Section
Hearing Research Study Section (HAR)
Project Start
1994-07-01
Project End
1999-03-31
Budget Start
1997-07-01
Budget End
1999-03-31
Support Year
4
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Southern Illinois University School of Medicine
Department
Surgery
Type
Schools of Medicine
DUNS #
City
Springfield
State
IL
Country
United States
Zip Code
62794
Sheehan, Kelly; Sheth, Sandeep; Mukherjea, Debashree et al. (2018) Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity. J Vis Exp :
Borse, Vikrant; Al Aameri, Raheem F H; Sheehan, Kelly et al. (2017) Epigallocatechin-3-gallate, a prototypic chemopreventative agent for protection against cisplatin-based ototoxicity. Cell Death Dis 8:e2921
Sheth, Sandeep; Mukherjea, Debashree; Rybak, Leonard P et al. (2017) Mechanisms of Cisplatin-Induced Ototoxicity and Otoprotection. Front Cell Neurosci 11:338
Al Aameri, Raheem F H; Sheth, Sandeep; Alanisi, Entkhab M A et al. (2017) Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol. PLoS One 12:e0177198
Jiang, Peng; Ray, Amrita; Rybak, Leonard P et al. (2016) Role of STAT1 and Oxidative Stress in Gentamicin-Induced Hair Cell Death in Organ of Corti. Otol Neurotol 37:1449-56
Kaur, Tejbeer; Borse, Vikrant; Sheth, Sandeep et al. (2016) Adenosine A1 Receptor Protects Against Cisplatin Ototoxicity by Suppressing the NOX3/STAT1 Inflammatory Pathway in the Cochlea. J Neurosci 36:3962-77
Mukherjea, Debashree; Ghosh, Sumana; Bhatta, Puspanjali et al. (2015) Early investigational drugs for hearing loss. Expert Opin Investig Drugs 24:201-17
Sheth, Sandeep; Brito, Rafael; Mukherjea, Debashree et al. (2014) Adenosine receptors: expression, function and regulation. Int J Mol Sci 15:2024-52
Brito, Rafael; Sheth, Sandeep; Mukherjea, Debashree et al. (2014) TRPV1: A Potential Drug Target for Treating Various Diseases. Cells 3:517-45
Jajoo, Sarvesh; Mukherjea, Debashree; Kaur, Tejbeer et al. (2013) Essential role of NADPH oxidase-dependent reactive oxygen species generation in regulating microRNA-21 expression and function in prostate cancer. Antioxid Redox Signal 19:1863-76

Showing the most recent 10 out of 52 publications